Karen Khalil, Ann Kataria, Renu Phillippupillai, Marissa Brokhof, Nicole Kenyon, Vineeta Kumar, Jeffrey Stern, Matt Harris
{"title":"The Impact of Specialty Pharmacy Mandates on the Solid Organ Transplant Population","authors":"Karen Khalil, Ann Kataria, Renu Phillippupillai, Marissa Brokhof, Nicole Kenyon, Vineeta Kumar, Jeffrey Stern, Matt Harris","doi":"10.1111/ctr.70288","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>A specialty pharmacy mandate is a rule by insurance companies requiring patients to obtain “specialty” medications from specific pharmacies. This study's objective was to evaluate the impact of these mandates on patient care and the solid organ transplantation population. Two surveys were distributed to transplant professionals within the American Society of Transplantation Communities of Practice (AST COPs) and the International Transplant Nurses Society (ITNS). In total, 167 respondents were included (<i>n</i> = 105 AST COPs, <i>n</i> = 62 ITNS). Most of the AST COP cohort identified as pharmacists (76%), followed by physicians (13%). Most respondents from the ITNS cohort identified their role as nurse/coordinator (97%). Sixty-two percent of respondents from the AST COPs and 48% of respondents from ITNS reported delays in discharge due to specialty pharmacy mandates within the past 12 months. Over 60% described delays in initiation of drug therapy related to these mandates. Additionally, 18%–34% of patients required additional outpatient visits and/or readmissions related to medication access issues in the setting of specialty pharmacy mandates. Over 50% of the time, patients paid out of pocket for medications to allow discharge if an override was not possible. Specialty pharmacy mandates delayed discharges, increased cost, and puts undue strain on the healthcare system for solid organ transplant recipients.</p>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 9","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70288","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
A specialty pharmacy mandate is a rule by insurance companies requiring patients to obtain “specialty” medications from specific pharmacies. This study's objective was to evaluate the impact of these mandates on patient care and the solid organ transplantation population. Two surveys were distributed to transplant professionals within the American Society of Transplantation Communities of Practice (AST COPs) and the International Transplant Nurses Society (ITNS). In total, 167 respondents were included (n = 105 AST COPs, n = 62 ITNS). Most of the AST COP cohort identified as pharmacists (76%), followed by physicians (13%). Most respondents from the ITNS cohort identified their role as nurse/coordinator (97%). Sixty-two percent of respondents from the AST COPs and 48% of respondents from ITNS reported delays in discharge due to specialty pharmacy mandates within the past 12 months. Over 60% described delays in initiation of drug therapy related to these mandates. Additionally, 18%–34% of patients required additional outpatient visits and/or readmissions related to medication access issues in the setting of specialty pharmacy mandates. Over 50% of the time, patients paid out of pocket for medications to allow discharge if an override was not possible. Specialty pharmacy mandates delayed discharges, increased cost, and puts undue strain on the healthcare system for solid organ transplant recipients.
期刊介绍:
Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include:
Immunology and immunosuppression;
Patient preparation;
Social, ethical, and psychological issues;
Complications, short- and long-term results;
Artificial organs;
Donation and preservation of organ and tissue;
Translational studies;
Advances in tissue typing;
Updates on transplant pathology;.
Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries.
Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.